Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Porfimer Sodium in Mesothelioma, Malignant: NCT03678350 Clinical Landscape Report 2026
16 October 2026
NCT03678350 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Abemaciclib in Mesothelioma, Malignant: NCT03654833 Clinical Landscape Report 2026
16 October 2026
NCT03654833 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Verzistobart in Uveal Melanoma: NCT03652077 Clinical Landscape Report 2026
16 October 2026
NCT03652077 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pemetrexed Dipotassium in Mesothelioma: NCT03655821 Clinical Landscape Report 2026
16 October 2026
NCT03655821 clinical landscape for Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pemetrexed Dipotassium in Mesothelioma: NCT03656549 Clinical Landscape Report 2026
16 October 2026
NCT03656549 clinical landscape for Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Efgartigimod Alfa in Myasthenia Gravis: NCT03669588 Clinical Landscape Report 2026
16 October 2026
NCT03669588 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vesleteplirsen in Muscular Dystrophy, Duchenne: NCT03675126 Clinical Landscape Report 2026
16 October 2026
NCT03675126 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bortezomib in Factor 8 Deficiency, Acquired: NCT03700229 Clinical Landscape Report 2026
16 October 2026
NCT03700229 clinical landscape for Factor 8 Deficiency, Acquired: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
PF-06952229 in Liver Cancer: NCT03685591 Clinical Landscape Report 2026
16 October 2026
NCT03685591 clinical landscape for Liver Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TRK-250 in Idiopathic Pulmonary Fibrosis: NCT03727802 Clinical Landscape Report 2026
16 October 2026
NCT03727802 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Edasalonexent in Muscular Dystrophy, Duchenne: NCT03703882 Clinical Landscape Report 2026
16 October 2026
NCT03703882 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ziritaxestat in Idiopathic Pulmonary Fibrosis: NCT03711162 Clinical Landscape Report 2026
16 October 2026
NCT03711162 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.